Your browser is no longer supported. Please, upgrade your browser.
CNCE [NASD]
Concert Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.58 Insider Own3.90% Shs Outstand32.68M Perf Week-3.65%
Market Cap207.77M Forward P/E- EPS next Y-2.77 Insider Trans-2.45% Shs Float25.20M Perf Month-36.96%
Income-72.90M PEG- EPS next Q-0.69 Inst Own78.40% Short Float2.32% Perf Quarter-41.95%
Sales7.90M P/S26.30 EPS this Y-20.40% Inst Trans10.47% Short Ratio1.32 Perf Half Y-30.60%
Book/sh4.01 P/B1.65 EPS next Y19.00% ROA- Target Price- Perf Year-30.23%
Cash/sh4.19 P/C1.58 EPS next 5Y- ROE- 52W Range5.47 - 13.50 Perf YTD-47.78%
Dividend- P/FCF- EPS past 5Y- ROI-55.30% 52W High-51.11% Beta0.63
Dividend %- Quick Ratio14.00 Sales past 5Y-34.70% Gross Margin- 52W Low20.66% ATR0.59
Employees70 Current Ratio14.00 Sales Q/Q-46.20% Oper. Margin- RSI (14)29.33 Volatility6.04% 7.06%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.56 Prev Close6.89
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 BMO Payout- Avg Volume444.10K Price6.60
Recom1.80 SMA20-7.40% SMA50-34.11% SMA200-35.54% Volume247,054 Change-4.21%
Dec-16-20Initiated Berenberg Buy $25
Mar-30-20Initiated Jefferies Buy $23
Oct-03-19Reiterated H.C. Wainwright Buy $29 → $25
Jun-24-19Initiated SunTrust Buy $30
Jun-13-19Upgrade Janney Neutral → Buy
Jun-13-19Reiterated H.C. Wainwright Buy $26 → $29
Sep-13-18Initiated Janney Neutral
Mar-09-18Upgrade Mizuho Neutral → Buy $23 → $27
Jan-12-18Downgrade Mizuho Buy → Neutral $23
Oct-26-17Initiated Mizuho Buy $23
Jul-24-17Initiated H.C. Wainwright Buy $20
Mar-07-17Reiterated Stifel Buy $21 → $31
Jul-01-16Initiated Stifel Buy $23
Sep-22-15Reiterated ROTH Capital Buy $22 → $32
Aug-12-15Initiated Brean Capital Buy $21
Nov-12-14Reiterated ROTH Capital Buy $28 → $21
Mar-10-14Initiated UBS Buy $25
Mar-02-21 07:00AM  
Feb-25-21 03:30PM  
07:00AM  
06:30AM  
Feb-24-21 02:38AM  
Feb-18-21 07:00AM  
Feb-01-21 03:47PM  
07:00AM  
Dec-30-20 09:00AM  
Dec-17-20 01:25PM  
Dec-16-20 12:02AM  
Nov-09-20 07:00AM  
Nov-06-20 04:01PM  
Nov-05-20 06:30AM  
06:00AM  
Nov-03-20 07:00AM  
Nov-01-20 08:57AM  
Oct-29-20 10:00AM  
07:00AM  
Oct-22-20 07:00AM  
Oct-13-20 07:00AM  
Sep-29-20 07:00AM  
Sep-08-20 07:00AM  
Aug-18-20 06:00AM  
Aug-12-20 08:06AM  
Aug-06-20 11:05AM  
07:00AM  
Jul-30-20 12:33PM  
07:00AM  
Jul-08-20 07:00AM  
Jul-06-20 11:44AM  
09:30AM  
Jun-30-20 12:00PM  
11:30AM  
Jun-24-20 10:39AM  
Jun-12-20 04:01PM  
May-26-20 07:00AM  
May-22-20 08:52AM  
May-12-20 09:14PM  
07:00AM  
May-01-20 12:30AM  
Apr-30-20 08:45AM  
07:00AM  
Apr-29-20 12:00PM  
Apr-23-20 07:00AM  
Apr-15-20 08:55AM  
Apr-01-20 07:00AM  
Mar-26-20 11:54AM  
Mar-12-20 12:13AM  
Feb-24-20 07:00AM  
Feb-20-20 07:00AM  
Jan-30-20 04:01PM  
Jan-28-20 09:00AM  
Jan-27-20 04:02PM  
04:01PM  
Jan-24-20 05:52AM  
Jan-22-20 08:40AM  
Dec-19-19 04:05PM  
Dec-16-19 05:54AM  
Dec-13-19 02:18PM  
Dec-02-19 07:00AM  
Nov-25-19 11:21PM  
Nov-12-19 07:00AM  
Nov-10-19 08:40AM  
Nov-07-19 08:15AM  
07:00AM  
Nov-06-19 07:00AM  
Nov-05-19 01:36PM  
Oct-31-19 10:35AM  
07:00AM  
Oct-12-19 03:15AM  
Oct-02-19 07:00AM  
Sep-27-19 11:48AM  
Sep-23-19 07:00AM  
Sep-19-19 10:32AM  
Sep-17-19 07:00AM  
Sep-12-19 07:00AM  
Aug-29-19 07:00AM  
Aug-27-19 12:17AM  
Aug-16-19 03:10PM  
Aug-06-19 05:12AM  
Aug-01-19 09:25AM  
Jul-25-19 07:00AM  
Jul-05-19 03:12PM  
Jun-13-19 05:05PM  
Jun-12-19 07:00AM  
Jun-05-19 07:00AM  
May-28-19 02:13PM  
May-16-19 07:00AM  
May-14-19 07:00AM  
May-07-19 01:51PM  
May-02-19 11:52AM  
08:01AM  
07:00AM  
Apr-29-19 07:00AM  
Apr-25-19 10:34AM  
07:00AM  
Apr-11-19 09:46AM  
07:00AM  
Apr-10-19 06:30AM  
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for the treatment of autoimmune and central nervous system disorders. Its product candidates include CTP-543, which is in Phase III clinical trials for the treatment of alopecia areata; CTP-692, a selective deuterium-modified analog of the endogenous amino acid and D-serine that is in Phase II trials for the treatment of schizophrenia; and AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease. The company has strategic collaborations with Avanir Pharmaceuticals, Inc.; Cipla Technologies; Processa Pharmaceuticals; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals was founded in 2006 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tung Roger DChief Executive OfficerFeb 17Sale7.2013,48097,056808,578Feb 17 09:42 PM
Stuart NancyChief Operating OfficerFeb 16Sale7.326,04944,279173,280Feb 17 09:34 PM
Munsie Jeffrey AChief Legal OfficerFeb 16Sale7.323,76327,54546,153Feb 17 09:31 PM
Cassella James VChief Development OfficerFeb 16Sale7.323,76327,54594,064Feb 17 09:27 PM
Becker Marc A.Chief Financial OfficerFeb 16Sale7.323,76327,54571,371Feb 17 09:21 PM
HUTT PETER BARTONDirectorAug 31Option Exercise3.793,53913,4137,963Sep 01 04:01 PM
Cassella James VChief Development OfficerAug 17Sale10.374,35445,15176,127Aug 19 05:44 PM
Becker Marc A.Chief Financial OfficerAug 17Sale10.242,87529,44053,434Aug 19 05:43 PM
Stuart NancyChief Operating OfficerJun 22Option Exercise3.7921,23880,492167,924Jun 24 09:02 AM
Stuart NancyChief Operating OfficerJun 22Sale11.3410,295116,694157,629Jun 24 09:02 AM
Tung Roger DChief Executive OfficerMar 13Option Exercise3.7914,60155,338752,758Mar 16 07:23 AM
Auchincloss Thomas GDirectorMar 12Buy8.521,50012,7736,500Mar 13 12:19 PM